Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)
ID: 357175Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357175

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-094.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)" aimed at researching the effects of climate change on cancer risk, prevention, and survivorship. This initiative encourages innovative studies that explore how environmental changes influence cancer risks and healthcare delivery, particularly focusing on health inequities among vulnerable populations. The funding supports a maximum project period of five years with no specified budget limit, and applications can be submitted starting January 5, 2025, with deadlines extending until February 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-094-Full-Announcement.html
    PAR-25-094.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity (FON: PAR-25-094) aimed at researching the impacts of climate change on the cancer control continuum. This funding opportunity supports innovative studies focused on understanding and mitigating the effects of climate change on cancer risk, prevention, and survivorship. Applicants are encouraged to explore how environmental changes influence cancer risks and healthcare delivery disruptions while emphasizing health inequities among vulnerable populations. The application process begins on January 5, 2025, with various submission due dates extending until February 2026. Eligible organizations include higher education institutions, non-profits, for-profits, and local governments. The maximum project period is five years with no set budget limit. Reviews will assess scientific merit based on significance, innovation, rigor, and the expertise of the investigative teams. Successful proposals must include climate change expertise and may involve diverse research approaches. This initiative is crucial in responding to the growing health challenges posed by climate change and aligning with NIH’s goal to enhance public health through advanced research.
    Similar Opportunities
    Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Impacts of Climate Change Across the Cancer Control Continuum," aimed at supporting innovative research on the effects of climate change on cancer risks, control, and survivorship. This R21 Exploratory/Developmental Research Grant encourages multidisciplinary studies that explore the relationship between climate change and cancer-related health disparities, necessitating collaboration with climate change experts. The grant offers a budget cap of $275,000 for a two-year project period, with applications opening on January 16, 2025, and closing on May 7, 2026. Interested applicants can find more information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity focused on the impacts of climate change across the cancer control continuum, designated as the R01 Clinical Trial Optional grant. This initiative aims to support innovative research that assesses the effects of climate-related changes on cancer risks, prevention, survivorship, and healthcare delivery, with an emphasis on developing interventions to address health disparities and enhancing climate-resilient healthcare systems. The funding opportunity is critical for advancing understanding in this area and promoting multidisciplinary research to tackle significant challenges in cancer care exacerbated by environmental changes. Interested applicants, including higher education institutions, non-profits, and various government entities, must submit their applications by May 7, 2026, and can find additional details and guidelines at the provided NIH link or by contacting grantsinfo@nih.gov.
    Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)" aimed at fostering innovative research on the intersection of climate change and cancer. This R21 Exploratory/Developmental Research Grant seeks to explore various aspects of cancer risks exacerbated by climate change, including environmental influences, healthcare disruptions, and health disparities, with a focus on multidisciplinary approaches and collaboration with climate change experts. The grant supports studies with budgets up to $275,000 over a two-year period, and eligible applicants include higher education institutions, nonprofits, state and local governments, and for-profit organizations. Interested parties should note that the application deadline is May 7, 2026, and can find more information at the provided link or contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem," aimed at supporting research projects that enhance cancer communication strategies. This initiative focuses on three key areas: the development of new cancer communication surveillance methods, the creation of rapid intervention strategies using innovative approaches, and the establishment of multilevel communication models that address the bidirectional influence of communication levels. The funding, which can provide up to $500,000 per year for a duration of up to five years, is intended to improve health outcomes related to cancer prevention and control, particularly in the context of addressing communication disparities and misinformation in the digital age. Interested applicants can find more information and guidelines for submission at the NIH Grants Information website, with the application period opening on January 5, 2025, and a submission deadline of September 7, 2025.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem," aimed at supporting research projects that enhance cancer communication strategies. The initiative focuses on three key areas: the application of new cancer communication surveillance methods, the development of rapid pilot interventions, and the creation of multilevel communication models that emphasize bidirectional influences in cancer prevention and control. This funding, available through R21 exploratory/developmental grants, provides up to $275,000 for a maximum of two years, with applications due starting January 16, 2025. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.